SHANGHAI RAAS BLOOD PRODUCTS CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.19 CNY | -0.96% |
|
+2.86% | -10.12% |
| Apr. 15 | Grifols Plans to Appoint Independent Directors Only to Audit, Compensation Committees | MT |
| Apr. 10 | Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake | RE |
| Sales 2023 * | 7.8B 1.08B | Sales 2024 * | 9.08B 1.25B | Capitalization | 48.25B 6.66B |
|---|---|---|---|---|---|
| Net income 2023 * | 2.17B 300M | Net income 2024 * | 2.52B 348M | EV / Sales 2023 * | 6.19 x |
| Net cash position 2023 * | - 0 | Net cash position 2024 * | - 0 | EV / Sales 2024 * | 5.32 x |
| P/E ratio 2023 * |
22.3
x | P/E ratio 2024 * |
19.1
x | Employees | 3,121 |
| Yield 2023 * |
0.51% | Yield 2024 * |
0.55% | Free-Float | 68.13% |
More Fundamentals
* Assessed data
More news
More news
| 1 day | +2.69% | ||
| 1 week | +3.86% | ||
| Current month | +2.25% | ||
| 1 month | +2.98% | ||
| 3 months | +5.99% | ||
| 6 months | +10.00% | ||
| Current year | -9.25% |
1 week
6.96
7.32
1 month
6.667.32
Current year
5.938.60
1 year
5.938.68
3 years
4.988.68
5 years
4.9811.16
10 years
4.9826.67
| Managers | Title | Age | Since |
|---|---|---|---|
Jun Xu
CEO | Chief Executive Officer | 60 | 11-12-31 |
Le Qi Chen
DFI | Director of Finance/CFO | 37 | 21-10-25 |
Wei Bing Hu
CHM | Chairman | 60 | 03-03-02 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 68 | 20-05-19 | |
Yue Wen Zheng
BRD | Director/Board Member | 62 | 07-04-26 |
David Ian Bell
BRD | Director/Board Member | 70 | 20-05-19 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.71% | 2 M€ | -14.14% | ||
| 0.69% | 2 M€ | -18.13% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 7.19 | -0.96% | 32 985 570 |
| 24-04-25 | 7.26 | +2.69% | 44,895,570 |
| 24-04-24 | 7.07 | +0.43% | 23,964,500 |
| 24-04-23 | 7.04 | -0.28% | 26,719,940 |
| 24-04-22 | 7.06 | +0.71% | 27,407,080 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotes
Shanghai RAAS Blood Products Co., Ltd. specializes in the research, development and manufacturing of plasma-derived therapeutics. The group's products include human albumin, immunoglobulin and coagulation factors (thrombin, fibrinogen, prothrombin and fibrin).
China accounts for 96.6% of net sales.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
7.26
CNY
Average target price
7
CNY
Spread / Average Target
-3.58%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.25% | 6.66B | |
| -4.66% | 87.53B | |
| +2.63% | 40.42B | |
| -21.76% | 29.48B | |
| +56.02% | 25.43B | |
| -14.78% | 15.59B | |
| -18.49% | 11.49B | |
| -15.61% | 11.1B | |
| -44.02% | 11.3B | |
| +4.19% | 8.75B |
- Stock Market
- Equities
- 002252 Stock
